ClinicalTrials.gg
CompletedNCT05767398Updated Oct 26, 2024

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

A Phase 1 interventional study of Zanubrutinib in Healthy Volunteers, sponsored by BeiGene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study to determine the bioequivalence of a zanubrutinib tablet compared to capsules in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 32.0 kg/m\^2, inclusive
  • In good health, determined by no findings from medical history, 12-lead ECGs, vital sign measurements, and clinical laboratory evaluations as assessed by the investigator or designee
  • Female participants must be of non- (surgically sterile or )

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee
  • Evidence of any infections (bacterial, viral, fungal, parasitic, COVID-19) within 4 weeks prior to the first dose of study drug, as determined by the investigator or designee
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator or designee
  • History or presence of an abnormal prior to the first dose of the study drug that, in the opinion of the investigator or designee, is
  • Abnormal liver function tests, as defined by (AST), alanine aminotransferase (ALT), or total > (ULN) range
  • Positive hepatitis panel and/or positive test

Note: Other protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.

    Drug: Zanubrutinib

  • Experimental
    Sequence 2

    Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.

    Drug: Zanubrutinib

Interventions

  • Administered as a tablet or capsule

    Also known as: BGB-3111, Brukinsa

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  2. Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  3. Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  4. Time of the maximum observed plasma concentration (Tmax)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  5. Apparent terminal elimination half-life (t1/2)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  6. Apparent volume of distribution (Vz/F)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  7. Rate of decrease of concentration in the terminal phase (λz)

    Time frame: Predose and up to 48 hours postdose up to Day 10

  8. Apparent oral clearance (CL/F)

    Time frame: Predose and up to 48 hours postdose up to Day 10

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 30 days after last dose; up to approximately 7 weeks

  2. Number of participants with clinically significant laboratory values

    Laboratory values are based on hematology, clinical chemistry, and urinalysis test results

    Time frame: Up to 30 days after last dose; up to approximately 7 weeks

  3. Number of participants with clinically significant electrocardiogram (ECG) results

    Time frame: Up to 30 days after last dose; up to approximately 7 weeks

  4. Number of participants with clinically significant vital sign measurements

    Vital sign measurements include supine blood pressure, supine pulse rate, respiratory rate, and oral body temperature

    Time frame: Up to 30 days after last dose; up to approximately 7 weeks

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Apr 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
Mar 14, 2023
StartActual
Mar 7, 2023
Primary completionActual
Apr 28, 2023
CompletionActual
Apr 28, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05767398
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Mar 7, 2023
Primary completion
Apr 28, 2023
Completion
Apr 28, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion